Activase
(Alteplase)ApprovedProtein / enzyme
RocheAlteplase is used to dissolve blood clots in patients who have had a heart attack or stroke, helping to restore blood flow and prevent permanent damage.[2] Activase is currently approved and in use across 13 indications[4].[1]
Activase is one of 285 small molecule programs targeting Heart Failure. It is currently in Approved.
13
Indications
74
Total Trials
10
Active Trials
284
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
206 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Activase
RocheApproved
Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Adriamycin
PfizerPreclinical
Savaysa
Daiichi SankyoPreclinical
Zemplar
AbbViePreclinical
Xifaxan
SSalix
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stroke18 trials
Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 4·NCT05910125·472 enrolled
Show 15 more trials
Dual IntraVenous Thrombolysis Approach (DIVA) in Patients With Medium-vessel-occlusion Strokes: a Retrospective Study
Completed·—··NCT05809921·294 enrolled
Early Recanalization After Intravenous Thrombolysis With Tenecteplase Versus Alteplase in Distal Vessel Occlusion Strokes
Completed·—··NCT05635786·319 enrolled
Ischemic stroke15 trials
24 Hours Treatment with Alteplase in Patients with Ischemic Stroke
Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04879615·372 enrolled
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）
Unknown status·—·Phase 2·NCT05281549·225 enrolled
Show 12 more trials
Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)
Withdrawn·—·Phase 2/3·NCT02180204
Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ）
Unknown status·—·Phase 3·NCT05745259·1,630 enrolled
The Prevalence and Associated Factors of Early Deterioration After Successful Recanalization in Acute Ischemic Stroke
Unknown status·—··NCT04978181·30 enrolled
Pulmonary Embolism7 trials
Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism
Terminated·—·Phase 4·NCT03988842·4 enrolled
Show 4 more trials
Stroke, Acute Ischemic3 trials
Acute Myocardial Infarction2 trials
25 more indications
Efficacy and Safety2 trials
Myocardial Infarction2 trials
Hemodialysis2 trials
Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function
Unknown status·—·N/A·NCT02225782·150 enrolled
Thrombolysis1 trial
TED1 trial
Tirofiban for Patients Treated With Alteplase
Terminated·—·Phase 2/3·NCT03357133·30 enrolled
Physical Activity1 trial
Retinal Artery Occlusion1 trial
Pleural effusion1 trial
Hemorrhage1 trial
Deep Vein Thrombosis1 trial
Prosthetic Valve Thrombosis1 trial
Infusion1 trial
Acute Respiratory Failure1 trial
COVID-191 trial
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
Completed·—·Phase 2·NCT04357730·50 enrolled
Safety and Efficacy1 trial
Hematopoietic and Lymphoid Cell Neoplasm1 trial
Regulatory
FDA Approval Timeline[5]
Nov 13, 1987
CATHFLO ACTIVASE
BLA BLA103172
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Activase drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Alteplase. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]